Fate Therapeutics Inc. | Mutual Funds
Mutual Funds that own Fate Therapeutics Inc.
FTIF SICAV - Franklin Biotechnology Discovery Fund
3,445,302
6.45%
-121,200
1.91%
06/30/2018
Fidelity Select Biotechnology Portfolio
2,778,087
5.2%
-41,300
0.39%
07/31/2018
Franklin Biotechnology Discovery Fund
2,321,477
4.34%
-52,300
2.04%
03/31/2018
Fidelity Growth Company Fund
1,806,165
3.38%
-9,800
0.05%
07/31/2018
Fidelity Small Cap Growth Fund
1,322,805
2.48%
-8,738
0.37%
04/30/2018
SPDR S&P Biotech ETF
1,255,992
2.35%
3,231
0.28%
09/06/2018
Vanguard Total Stock Market Index Fund
1,180,892
2.21%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,040,111
1.95%
-555
0.03%
09/06/2018
Vanguard Extended Market Index Fund
576,988
1.08%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
474,791
0.89%
0
0.05%
09/06/2018
| Address |
3535 General Atomics Court
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.fatetherapeutics.com |
| Updated |
07/08/2019 |
| Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. |
